Clinical outcomes of a digital musculoskeletal women's pelvic health program: an observational, longitudinal study with comparison group.

Background: Chronic pelvic pain is a common yet undertreated condition that significantly impacts quality of life for women worldwide. Digital exercise therapy designed to target pelvic pain can improve symptomology while reducing time and cost-related barriers to in-person clinical care.

Methods: This longitudinal, observational study of a digital women's pelvic health program examined pelvic pain, anxiety, and depression at 4 and 12 weeks in female adults experiencing chronic pelvic pain.

Bioleaching of lithium from jadarite, spodumene, and lepidolite using .

Lithium (Li) is becoming increasingly important due to its use in clean technologies that are required for the transition to net zero. Although acidophilic bioleaching has been used to recover metals from a wide range of deposits, its potential to recover Li has not yet been fully explored. In this study, we used a model Fe(II)- and S-oxidising bacterium, (At.

The Europa Imaging System (EIS) Investigation.

The Europa Imaging System (EIS) consists of a Narrow-Angle Camera (NAC) and a Wide-Angle Camera (WAC) that are designed to work together to address high-priority science objectives regarding Europa's geology, composition, and the nature of its ice shell. EIS accommodates variable geometry and illumination during rapid, low-altitude flybys with both framing and pushbroom imaging capability using rapid-readout, 8-megapixel (4k × 2k) detectors. Color observations are acquired using pushbroom imaging with up to six broadband filters.

Pharmacokinetics, Pharmacodynamics, Bioavailability, and Immunogenicity of Obexelimab Following Subcutaneous Administration in Healthy Japanese and Non-Japanese Volunteers.

Introduction: Obexelimab is an investigational, bifunctional, non-depleting, humanized monoclonal antibody that binds CD19 and FcγRIIb to inhibit B cells, plasmablasts, and CD19-expressing plasma cells. In clinical trials, intravenous (IV) administration of obexelimab has been well-tolerated, and demonstrated clinical activity in patients with rheumatoid arthritis, systemic lupus erythematosus, and immunoglobulin G4-related disease. This study was performed to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of obexelimab following subcutaneous (SC) administration, and compare PK/PD profiles between healthy Japanese and non-Japanese volunteers.